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The American Society for Microbiology and Molecular and Cellular Biology would like to inform readers that this article is a corrected and republished version of one (https://doi.org/10.1128/MCB.00802-12) which was retracted
(https://doi.org/10.1128/MCB.00477-17). The original article was found to have image
duplications in Fig. 2, 5, 6, and 7. Most of the duplications occurred in loading controls,
such as ␤-actin and GAPDH, but were not limited to this. Owing to the number of
ﬁgures affected, a correction was not allowed and the article was retracted. However,
the authors were able to provide the original data that supported the results and
conclusions presented in the article. Therefore, the authors were allowed to submit a
revised manuscript for consideration.
PUBLISHER’S NOTE

ABSTRACT The transcription factor interferon regulatory factor 5 (IRF5) exerts crucial functions in the regulation of host immunity against extracellular pathogens,
DNA damage-induced apoptosis, death receptor signaling, and macrophage polarization. Tight regulation of IRF5 is thus warranted for an efﬁcient response to extracellular stressors and for limiting autoimmune and inﬂammatory responses. Here we report that the COP9 signalosome (CSN), a general modulator of diverse cellular and
developmental processes, associates constitutively with IRF5 and promotes its protein stability. The constitutive CSN/IRF5 interaction was identiﬁed using proteomics
and conﬁrmed by endogenous immunoprecipitations. The CSN/IRF5 interaction occurred on the carboxyl and amino termini of IRF5; a single internal deletion (Δ455466) was found to signiﬁcantly reduce IRF5 protein stability. CSN3 was identiﬁed as
a direct interacting partner of IRF5, and knockdown of this subunit with small interfering RNAs (siRNAs) resulted in enhanced degradation. Degradation was further
augmented by knockdown of CSN1 and CSN3 together. The ubiquitin E1 inhibitor
UBEI-41 or the proteasome inhibitor MG132 prevented IRF5 degradation, supporting
that its stability is regulated by the ubiquitin-proteasome system. Importantly, activation of IRF5 by the death receptor ligand tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL) resulted in enhanced degradation via loss of the
CSN/IRF5 interaction. This study deﬁnes the CSN as a new interacting partner of IRF5
that controls its stability.
KEYWORDS COP9, IRF5

T

he interferon regulatory factor (IRF) family consists of nine cellular IRFs, each
with pleiotropic biological functions (1). IRF5 has an important role in the
induction of type I interferons (IFNs) and proinﬂammatory cytokines and is thus a
critical mediator of innate and adaptive immunity (2–4). More recent studies have
shown that Irf5 is an autoimmune susceptibility gene associated with increased risk of
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human systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjögren’s
syndrome (5–9). In addition to being one of the key factors mediating MyD88dependent Toll-like receptor (TLR) signaling, mouse and human cells lacking Irf5 are
resistant to undergoing DNA damage- or death receptor-induced apoptosis, supporting
a critical role for IRF5 in the cellular response to a variety of extracellular stressors
(10–14). To this extent, loss of IRF5 expression in both mouse and human cells has
recently been shown to contribute to tumorigenesis and metastasis (4, 10, 14, 15).
IRF5 is a latent transcription factor that is constitutively expressed in most hematopoietic cells and can be upregulated in many other cell types in response to type I
IFNs or DNA damage (2, 10, 14, 16, 17). IRF5 resides in the cytoplasm of most
unstimulated cells and becomes activated by posttranslational modiﬁcations that
include phosphorylation, acetylation, and/or ubiquitination, resulting in translocation
to the nucleus (2, 13, 18–22). While all IRF family members share signiﬁcant homology
in their amino-terminal DNA binding domain (DBD), the carboxyl terminus of individual
IRFs is not well conserved and thus is thought to dictate speciﬁc interactions with other
proteins and IRF family members that control/mediate their distinct functions (1, 21).
Little is still known of IRF5-interacting partners. We and others and have identiﬁed a few
proteins that interact with IRF5, including IRF1, IRF3, IRF7 (23), CBP/p300, histone
deacetylases (5, 21), TRAF6, MyD88, IRAK1, and IRAK4 (3, 18). The exact functional
consequences of each of these interactions have not been fully elucidated, but most
are thought to be associated with IRF5 activation.
In the current study, we identiﬁed the constitutive photomorphogenesis 9 (COP9)
signalosome as a new interacting partner of IRF5 in unstimulated cells. The COP9
signalosome (CSN) is a highly conserved protein complex that consists of eight subunits
known as CSN1 to CSN8 (24, 25). The complex was ﬁrst discovered in Arabidopsis as a
suppressor of light-dependent growth (26–28), and subsequent work identiﬁed and
characterized the CSN in mammals (24, 25), yeast (29), fungi (30), and Caenorhabditis
elegans (31), highlighting its role as a general modulator of diverse cellular and
developmental processes. The most well-studied function of the CSN is its regulation of
protein degradation, and research in a variety of organisms has supported the notion
that the CSN is biochemically linked to the ubiquitin-proteasome pathway (32–37).
Equally interesting and potentially important to the regulation of IRF5 function is the
ability of the CSN to act as a scaffold to control/mediate phosphorylation of transcriptional regulators through the activity of CSN-associated kinases (reviewed in reference
38). Kinase signaling and ubiquitin-mediated protein degradation are generally not
mutually exclusive, and phosphorylation often regulates protein degradation. The CSN
has also been shown to regulate the subcellular localization of different signaling
molecules (39, 40).
The goal of the present study was to characterize the functional consequence of this
newly identiﬁed CSN/IRF5 interaction in unstimulated cells and to determine how the
resulting function may be altered in response to a stimulus that induces IRF5 activation.
Collectively, we found that the CSN/IRF5 interaction controls IRF5 protein stability via
interaction with both the carboxyl and amino termini of IRF5. Loss of the CSN/IRF5
interaction resulted in enhanced degradation that was mediated by the ubiquitinproteasome pathway and further enhanced by tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL)-induced IRF5 activation.
RESULTS
Interaction of COP9 subunits with IRF5. To identify proteins that interact with
IRF5, a proteomics-based approach was used. A plasmid encoding the full-length
Flag-tagged IRF5 variant 3/4 was transiently transfected into Hek 293T cells that
otherwise lack endogenous IRF5. Proteins that immunoprecipitated with anti-Flag
antibodies (IRF5) were resolved by one-dimensional sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and stained with SYPRO ruby, and
bands were cut and identiﬁed by mass spectrometry (MS) analysis. In addition to
conﬁrming the presence of high levels of ectopic Flag-tagged IRF5 at ⬃60 kDa in
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FIG 1 Identiﬁcation of the COP9 signalosome as a novel interacting partner of IRF5. (A) Representative gel image from the transient transfection of Flag-tagged
IRF5 (IRF5) or empty Flag-tagged vector control (EV) to Hek 293T cells. Lysates were immunoprecipitated with anti-Flag M2 antibodies, and proteins bound to
beads were separated by SDS-PAGE. Proteins were stained with SYPRO ruby, and the indicated bands were excised for LC/MS-MS analysis. The molecular mass
(MM) marker is shown on the left. (B) Same as that described for panel A except that immunoprecipitated lysates were separated by 2-D gel electrophoresis.
A representative gel image from cells overexpressing Flag-tagged IRF5 is shown. The gel was stained with SYPRO ruby, and the indicated spots that were unique
to cells expressing IRF5 compared to EV control cells were excised for LC/MS-MS analysis. (C) Same as that described for panel A except that resolved proteins
were immunoblotted with antibodies speciﬁc for each COP9 subunit. The IRF5 input and loading control ␤-actin are shown. (D) Similar to that described for
panel C except that THP-1 cells were immunoprecipitated with IgG isotype control antibodies or anti-IRF5 antibodies. COP9 subunits were identiﬁed by
immunoblot analysis.

the IRF5-transfected cells, we identiﬁed another unique band at ⬃35 kDa that was
not present in empty vector control cells (Fig. 1A). Analysis of this band by liquid
chromatography-tandem MS (LC/MS-MS) revealed that it consisted primarily of the
COP9 subunit 7 isoform b (gi 12232385) with a conﬁdence interval of ⱖ95%. COP9
subunit 7 (CSN7) is the seventh subunit of the COP9 signalosome complex, which has
February 2018 Volume 38 Issue 3 e00493-17

mcb.asm.org 3

Korczeniewska and Barnes

Molecular and Cellular Biology

been shown to interact with Int6/eIF3, casein kinase 2 (CK2), and PMF-1 (41–43). CSN7
can itself be phosphorylated and can interact with kinases, supporting the idea that the
CSN is a central component of kinase-mediated signal transduction pathways (24, 42,
44–46).
In a similar independent experiment whereby proteins that immunoprecipitated
with anti-Flag antibodies were resolved by two-dimensional (2-D) gel electrophoresis in
order to obtain more detailed insight into the proteins that may be interacting with
IRF5, we were able to detect another COP9 subunit, CSN4, in the pulled-down precipitate (Fig. 1B). Little is known of CSN4 function in mammalian cells, yet CSN4 to CSN7
(CSN4-7) have previously been designated a mini-CSN subcomplex (47).
To conﬁrm the interaction of IRF5 with the CSN, and to determine whether additional subunits could be detected as interacting with IRF5, we performed immunoprecipitation of Flag-tagged IRF5 in Hek 293T cells and immunoblotted resolved proteins
with antibodies speciﬁc to each CSN subunit. We found that all CSN subunits could be
pulled down in the cells overexpressing IRF5 and not empty vector control cells
(Fig. 1C). To further conﬁrm these interactions, we immunoprecipitated endogenous
IRF5 from THP-1 cells, which express high levels of IRF5, and immunoblotted with
individual CSN subunit antibodies. Similar to data in Fig. 1C, we detected a speciﬁc
interaction of all subunits with IRF5, since these interactions were absent in THP-1 cells
immunoprecipitated with anti-IgG control antibodies (Fig. 1D).
Mapping CSN binding to the amino and carboxyl termini of IRF5. We next
mapped the domain of IRF5 responsible for interaction with the CSN. Like most IRF
family members, IRF5 possesses a protein-interacting domain in its carboxyl terminus
(Fig. 2A), so we focused on this region ﬁrst for detection of CSN binding. A series of
carboxyl-terminal deletion mutants were generated and transiently transfected individually to Hek 293T cells, and lysates were immunoprecipitated with anti-Flag antibodies. Binding of endogenous CSN subunits to Flag-tagged IRF5 was determined by
immunoblotting with anti-CSN subunit-speciﬁc antibodies. Construct 1-489, representing full-length IRF5 (comprising amino acids [aa] 1 to 489), and consecutively shorter
constructs 1-477, 1-411, 1-326, and 1-246 were tested for their interaction with CSN
subunits. Interaction of individual subunits with full-length IRF5 and the 1-477 deletion
mutant was detected (Fig. 2B); interaction was absent in the shorter constructs,
indicating that CSN subunits interact between aa 411 to 477 of IRF5. Consecutively
shorter mutants were generated in this region, and a distinct loss of interaction was
observed between aa residues 433 to 444 and 455 to 466 (Fig. 2C). The altered binding
pattern between aa 422 and 466 may reﬂect true interactions or may be an artifact of
the entire three-dimensional structure of IRF5 changing due to the large deletions at
the carboxyl terminus. To address whether both of these regions are essential for
interaction with the CSN, we generated Δ433-444 and Δ455-466 internal deletion
mutants for immunoprecipitation experiments. We found that only the mutant lacking
aa 455 to 466 was incapable of interacting with the CSN (Fig. 2D).
In a similar manner, we examined the ability of the CSN to interact with the
amino-terminal DNA binding domain of IRF5. In previous work, we had identiﬁed a
carboxyl-terminal autoinhibitory domain (AID) of IRF5 that was proposed to mask the
amino-terminal DNA binding domain in unstimulated cells, supporting a closed structure for inactive IRF5 monomers (19). Subsequent crystallography data supported the
presence of a functional IRF5 AID that masks the DNA binding domain in unstimulated
cells (48). Similar to the carboxyl-terminal mapping, a number of amino-terminal
deletion mutants were generated and analyzed for interaction with CSN subunits (data
not shown). Eventually, the region interacting with the CSN was narrowed down to aa
41 to 50 (Fig. 2E). Taking into account data from the carboxyl-terminal IRF5 internal
deletion mutants (Fig. 2D), we found that both regions (aa 41 to 50 and 455 to 466) are
required for interaction of IRF5 with the CSN and support a folded conformation
whereby the carboxyl terminus of IRF5 is folded over the amino-terminal DNA binding
domain.
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FIG 2 The CSN interacts with the amino and carboxyl termini of IRF5. (A) Scheme of the IRF5 protein structure with functional domains and newly generated
carboxyl-terminal deletion mutants. NLS, nuclear localization signal; NES, nuclear export signal; PEST, region rich in proline (P), glutamic acid (E), serine (S), and
threonine (T) residues; AID, autoinhibitory domain. (B) Full-length Flag-tagged IRF5 and the indicated carboxyl-terminal deletion mutant plasmids were
transiently transfected into Hek 293T cells and immunoprecipitated with anti-IRF5 antibodies, and binding of CSN subunits to IRF5 was detected by
immunoblotting with antibodies speciﬁc to each subunit. Input lysates from each transfection are shown at the bottom with ␤-actin levels that serve as a
loading control. (C) Same as that described for panel B except that additional carboxyl-terminal deletion mutants were generated and tested for their ability
to interact with COP9 subunits. (D) The CSN interacts with IRF5 between aa 455 and 466. Same as that described for panels B and C except that internal deletion
mutants of IRF5 were transiently transfected into Hek 293T cells. (E) Same as that described for panel D except that amino-terminal IRF5 internal deletion
mutants were transiently transfected into Hek 293T cells and interaction with individual COP9 subunits was determined by immunoblotting.

We next sought to determine which subunit(s) might be interacting directly with
IRF5. Using the TNT quick coupled transcription/translation assay, we generated cellfree recombinant IRF5, CSN2, CSN3, and CSN5 proteins for coimmunoprecipitation
experiments. All four proteins were produced at a high yield, and equal amounts of IRF5
were coincubated with equal amounts of each CSN subunit; only CSN3 was detected as
interacting directly with IRF5 (Fig. 3).
CSN controls IRF5 protein stability. Given that the interaction between IRF5 and
the CSN occurs in unstimulated cells, combined with the fact that the most well-studied
function of the CSN is regulation of protein stability, we postulated that this interaction
might control IRF5 stability. Little to nothing is known of IRF5 protein stability. We
previously identiﬁed a large PEST domain in the IRF5 protein sequence (illustrated in
Fig. 2A) and hypothesized that it would control IRF5 protein stability (19). The PEST
February 2018 Volume 38 Issue 3 e00493-17
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FIG 3 COP9 subunit 3 directly interacts with IRF5. Cell-free recombinant IRF5, CSN2, CSN3, and CSN5
proteins were generated using the TNT quick coupled transcription/translation assay for coimmunoprecipitation experiments. Western blot analysis of the four proteins shows input for each coimmunoprecipitation; equal amounts of IRF5 were used in each assay. Only the interaction of CSN3 with IRF5 was
detected after immunoprecipitating for IRF5.

domain is a region rich in proline (P), glutamic acid (E), serine (S), and threonine (T)
residues and is thought to target proteins for proteolytic degradation. However, recent
data from our laboratory indicate that the PEST domain has little to do with IRF5 protein
stability since the IRF5 isoform V5, which contains an intact PEST domain, is signiﬁcantly
more stable than V8, which lacks the entire PEST domain (17, 19, 86). These data
support that additional mechanisms that control IRF5 protein stability exist.
To determine whether the CSN/IRF5 interaction controls IRF5 protein stability, we
compared the stability of full-length IRF5 proteins with that of IRF5 proteins encoded
by the Δ455-466 mutant by cycloheximide (CHX) chase. Full-length Flag-tagged IRF5
and Δ455-466 plasmids were transiently transfected into Hek 293T cells and left
untreated or treated with CHX over a time course; protein levels were analyzed by
immunoblotting with anti-Flag antibodies. Data in Fig. 4A indicate enhanced degradation of IRF5 proteins lacking the CSN interaction domain between aa 455 and 466; data
in Fig. 4B, from parallel untreated samples, indicate the speciﬁcity of CHX treatments.
To obtain more quantitative insight into the CSN=s control of IRF5 protein stability/
degradation, we used a modiﬁed CHX chase technique whereby Hek 293T cells,
transiently transfected with green ﬂuorescence protein (GFP)-tagged full-length IRF5
or the Δ455-466 mutant, were fractionated by ﬂuorescence-activated cell sorting (FACS)
into subpopulations expressing “low,” “medium,” and “high” levels of GFP. Only the
medium level-expressing cells, shown to be the most sensitive to CHX (49), were
subjected to CHX treatment. The absolute slope of decreasing mean ﬂuorescence
intensity (MFI) over time (reﬂecting relative half-life and stability) was determined.
Full-length GFP-IRF5 had the smallest decrease in MFI over time and therefore a smaller
absolute slope, while the Δ455-466 mutant had the larger decrease in MFI and a steeper
slope (Fig. 4C). Representative histogram plots of ﬂuorescence distribution and gating
are shown for the full-length and mutant proteins, revealing similar distributions (Fig.
4D). These data support ﬁndings from immunoblot analysis showing that the IRF5
Δ455-466 mutant degrades faster than full-length IRF5. Comparable data were obtained by standard ﬂow cytometric analysis of total IRF5 expression after treatment of
cells with CHX (Fig. 4E and F). Both sets of ﬂow cytometric data gave a signiﬁcant
difference between the absolute slopes of full-length IRF5 and the Δ455-466 construct,
indicating that loss of the CSN interaction signiﬁcantly decreases IRF5 protein stability
(Fig. 4C and E). As a positive control, the ability of GFP-IRF5 fusion proteins to interact
with COP9 subunits was tested by immunoprecipitation; similar to their Flag-tagged
counterparts, full-length GFP-IRF5 interacted with all COP9 subunits while the GFPtagged Δ455-466 mutant was unable to interact (Fig. 2 and 4G).
Knockdown of CSN1 and CSN3 promotes IRF5 degradation. It has previously
been shown that downregulation of CSN1 and CSN3 by speciﬁc small interfering RNAs
February 2018 Volume 38 Issue 3 e00493-17
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FIG 4 CSN/IRF5 interaction controls IRF5 protein stability. (A) Plasmids encoding full-length (FL) and mutant (Δ455-466) Flag- or GFP-tagged IRF5 were
transiently transfected into Hek 293T cells and chased with cycloheximide (CHX). Cells were harvested at the indicated time points post-CHX treatment, and
proteins were separated by SDS-PAGE. Protein levels were determined by immunoblot (IB) analysis with anti-IRF5 and anti-␤-actin antibodies. (B) Same as that
described for panel A except that cells were left untreated and harvested at each indicated time point. (C) Cells expressing medium levels of GFP-IRF5 were
sorted and treated with CHX for the indicated time periods and then gated on by ﬂow cytometry to determine the intracellular levels of IRF5. GFP intensity
was quantiﬁed at each time point and plotted on a graph as a function of time. The rate of exogenous protein decay was determined by ﬁtting a line to each
data set and calculating the slope. Representative results from two independent replicates are shown (IRF5a and b; Δ455-466a and b); the average rate of decay
was calculated from three independent experiments performed in duplicate. P ⬍ 0.05 by paired two-tailed Student t test. (D) Representative histograms of
ﬂuorescence distribution and sorting of cells expressing medium (R3⫹R4) levels of GFP-tagged full-length and mutant IRF5 proteins. The purity of sorted cells
that were treated with CHX is shown. (E) Same as that described for panel C except that the total cells transfected with either plasmid were treated with CHX
over the indicated time periods and IRF5 levels were determined by ﬂow cytometry. (F) Same as that described for panel D except that representative
histograms show the strategy of gating on GFP-IRF5-positive cells. The geometric mean was obtained from the subset of cells indicated in the ﬂuorescence
histograms. An overlay of the two experimental conditions is shown. (G) Full-length (FL) and mutant (Δ) GFP-IRF5 proteins were transiently transfected into Hek
293T cells, lysates were immunoprecipitated with anti-IRF5 antibodies, and the interaction with individual COP9 subunits was determined by immunoblotting.

(siRNAs) targeting these two subunits leads to an approximately 40% reduction of the
subunits and a proportional reduction of the entire CSN complex (50). Since we have
found that CSN3 interacts directly with IRF5 (Fig. 3), we examined the effect of targeting
CSN3 or both subunits (CSN1 and CSN3) on IRF5 protein stability. Speciﬁc siRNAs
targeting each of these subunits were transiently cotransfected into Hek 293T cells with
plasmids encoding full-length Flag-tagged IRF5 or the Δ455-466 mutant and treated
with CHX over a time course. Expression of IRF5 and the subunits was determined by
immunoblot analysis (Fig. 5A). Similar to what was observed in Fig. 4A, IRF5 Δ455-466
proteins degraded more rapidly than full-length IRF5 even in the presence of control
siRNAs (Ctr siRNA); no effect of the control siRNAs on IRF5, CSN1, CSN3, or GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) expression was observed. Although
February 2018 Volume 38 Issue 3 e00493-17
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FIG 5 Knockdown of CSN1 and CSN3 promotes IRF5 degradation. (A) Plasmids encoding full-length (FL) IRF5 or the Δ455-466 mutant were transiently
cotransfected with control siRNAs (Ctr siRNA) or siRNAs targeting CSN1, CSN3, or the combination of the two, into Hek 293T cells. Cells were then treated with
CHX, and protein expression was analyzed over the indicated time periods post-CHX treatment. Knockdown efﬁciency for each siRNA is shown for each
independent transfection; GAPDH levels are shown as an internal loading control. Representative data from three independent experiments are shown. (B)
Quantitation of IRF5 expression from panel A after densitometry analysis using ImageJ software; means ⫾ SD are plotted from three independent experiments.
The point at which the effect of the CSN1/3 knockdown on IRF5 FL stability becomes statistically signiﬁcant is shown; *, P ⬍ 0.001 by Student’s t test. (C) Same
as that described for panel A except that siRNAs were transiently transfected into THP-1 cells and endogenous IRF5 and CSN subunits 1 and 3 were examined
by immunoblotting with speciﬁc antibodies. Representative data from three independent experiments are shown. (D) Same as that described for panel B except
that relative IRF5 expression from panel C is quantiﬁed; means ⫾ SD are plotted from three independent experiments. The point at which the effect of the
CSN1/3 knockdown on IRF5 stability becomes statistically signiﬁcant is shown; *, P ⬍ 0.01 by Student’s t test. (E) Same as that described for panel C except
that siRNAs targeting CSN5 were transfected into THP-1 cells and their effect on IRF5 expression was examined. Representative data from three independent
experiments are shown.

nearly 100% knockdown of CSN1 and CSN3 expression was achieved, little effect of the
CSN1 knockdown on IRF5 expression was observed, while knockdown of CSN3 on its
own achieved a dramatic decrease in IRF5 expression at 8 h. Interestingly, knockdown
of both CSN1 and CSN3 at the same time gave a degradation pattern for full-length
IRF5 similar to that seen with the Δ455-466 mutant. As expected, knockdown of both
CSN1 and CSN3 in cells expressing IRF5 Δ455-466 proteins had no effect on degradation. Quantitation of these data is shown in Fig. 5B.
February 2018 Volume 38 Issue 3 e00493-17
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Similar data were obtained when CSN siRNAs were transiently transfected into
THP-1 cells and endogenous IRF5 protein levels were examined after treatment of cells
with CHX (Fig. 5C). In this experiment, knockdown of CSN1 by itself gave a reduction
in IRF5 levels at 8 h post-CHX treatment and CSN3 knockdown resulted in an even more
rapid decay of IRF5 proteins that occurred between 2 and 4 h post-CHX treatment. The
combined knockdown of CSN1 and CSN3 was the most effective in reducing IRF5
protein stability. Quantitation is shown in Fig. 5D. As a negative control, we examined
whether knockdown of another COP9 subunit, CSN5, which does not directly interact
with IRF5 (Fig. 3) or affect the CSN complex (50), would have an effect on IRF5 stability.
Data in Fig. 5E demonstrate that loss of CSN5 has no effect on IRF5 degradation.
Together, these data support a clear and important role for CSN3 and the entire CSN
complex in regulating IRF5 protein stability.
IRF5 degradation is regulated by the ubiquitin-proteasome pathway. One of
the best-characterized functions of the CSN is the control of proteolysis via the
ubiquitin-proteasome pathway (34). Ubiquitylation is catalyzed by the sequential action
of ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and a ubiquitin
protein ligase (E3). Ubiquitylation is essential to numerous cellular and developmental
processes, including, but not limited to, protein quality control, growth, apoptosis,
antigen presentation, DNA repair, and signal transduction (42, 51–57). The most
well-characterized role for ubiquitin is in targeting proteins for degradation by the 26S
proteasome after modiﬁcation with chains of four or more ubiquitins. To test whether
CSN-dependent stabilization of IRF5 is due to altered recognition of IRF5 by the
ubiquitin-proteasome pathway, Hek 293T cells expressing full-length IRF5 or the Δ455466 mutant were treated with the E1 ubiquitin inhibitor UBEI-41 or the proteasome
inhibitor MG132 in conjunction with CHX. E1 inhibitors target the common ﬁrst step in
ubiquitylation, and MG132 targets the ﬁnal destination for many ubiquitylated proteins.
The rate of IRF5 protein decay was measured by immunoblot analysis. Consistent with
the data in Fig. 4 and 5, the observed reduction in full-length IRF5 protein levels over
time after treatment of cells with CHX was greatly enhanced in the mutant lacking the
ability to interact with the CSN (Fig. 6A). However, treatment of full-length or Δ455-466
IRF5-expressing cells with UBEI-41 or MG132 protected IRF5 from degradation (Fig. 6A).
This effect was speciﬁc for IRF5, as no change in GAPDH protein levels was
observed. These results suggest that the CSN/IRF5 interaction protects IRF5 from
ubiquitination and degradation by the 26S proteasome pathway.
IRF5 undergoes K48-linked ubiquitination in the absence of the CSN/IRF5
interaction. The most abundant polyubiquitin chains in living cells are K48 linkages,
which adopt a closed conformation and serve as a signal for target protein degradation
by the 26S proteasome. The next most common are K63 linkages that adopt an
extended linear conformation as nonproteasome recognizing and often lead to the
activation of signaling functions. To this extent, it has previously been shown that IRF5
undergoes TRAF6-mediated K63-linked ubiquitination when IRF5, MyD88, and TRAF6
are overexpressed in Hek 293 cells (18). The TRAF6-mediated K63-linked ubiquitination
of IRF5 led to its nuclear translocation and enhanced transactivation potential (18).
Based on these ﬁndings and the new data in Fig. 6A suggesting that IRF5 becomes
ubiquitinated when it is unable to interact with the CSN, we examined IRF5 ubiquitination in Hek 293T cells cotransfected with hemagglutinin-ubiquitin (HA-Ub) and
full-length IRF5 or the Δ455-466 mutant. It was not surprising that we detected
polyubiquitination of the Δ455-466 mutant and not of full-length IRF5 (Fig. 6B). Using
an antibody that speciﬁcally recognizes K48-linked ubiquitination, we were able to
characterize the polyubiquitination as K48 linked. These data support the premise that
the interaction of IRF5 with the CSN protects it from undergoing K48-linked ubiquitination and degradation by the 26S proteasome pathway.
Activation of IRF5 by TRAIL enhances degradation. It is well known that many
proteins that become phosphorylated in response to a given stimuli are subsequently
ubiquitinated, followed by proteasome-dependent degradation (32, 44). IRF5 is
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FIG 6 IRF5 degradation is abrogated by the inhibition of ubiquitin activating enzyme 1 (E1) or the proteasome. (A) Plasmids encoding full-length
IRF5 or the Δ455-466 mutant were transiently transfected into Hek 293T cells and treated with CHX or CHX plus UBE-41 (ubiquitin E1 inhibitor)
or MG132 (proteasome inhibitor). The rate of IRF5 and GAPDH protein decay was examined by immunoblot analysis. Panels are labeled by
treatment regimen. (B) Similar to that described for panel A except that the HA-Ub plasmid was cotransfected with plasmids encoding empty
vector (lane C), full-length IRF5 (lane FL), or Δ455-466 mutant IRF5 (lane Δ) into Hek 293T cells to examine IRF5 ubiquitination. Reciprocal
immunoprecipitations are shown by pulling down IRF5 (M2) or ubiquitin (HA). Levels of IRF5 and ␤-actin are shown in whole-cell lysates used
for immunoprecipitations. (C) Similar to that described for panel B except that cells were not transfected with HA-Ub and the levels of IRF5
K48-linked ubiquitination were determined by immunoblotting M2 precipitates with anti-K48-linked polyubiquitination antibodies. Expression of
IRF5 and ␤-actin in whole-cell lysates used for the immunoprecipitations is shown.

thought to be activated by phosphorylation in response to different extracellular
stimuli, including virus, DNA damage, MyD88-dependent TLR ligands, and the death
receptor ligand TRAIL (2, 3, 12, 13, 19, 20, 58), resulting in its biological activity. In order
to test the functional signiﬁcance of the CSN/IRF5 interaction in a cellular system known
to activate endogenous IRF5 via phosphorylation of serine (Ser), threonine (Thr), and
tyrosine (Tyr) residues (12), we treated THP-1 cells with TRAIL and examined whether
IRF5 activation had any effect on its degradation. To begin these studies, we ﬁrst
conﬁrmed that TRAIL could induce endogenous IRF5 nuclear localization. In our ﬁrst
study, while we were able to examine endogenous IRF5 phosphorylation, the appropriate reagents were not available to examine its endogenous cellular localization (12).
We have recently optimized the use of imaging ﬂow cytometry to examine endogenous
IRF5 activation/nuclear localization in primary immune cells of patients with SLE (59).
Using this same technology, we examined quantitatively the ability of TRAIL to
induce endogenous IRF5 nuclear localization in THP-1 cells over time. Figure 7A shows
representative images of cells costained with ﬂuorescein isothiocyanate (FITC)conjugated IRF5 and DRAQ5, a nuclear-speciﬁc stain. By examining similarity scores
between DRAQ5 and IRF5 (as described in Materials and Methods), we found that
⬎50% of cells staining positive for IRF5 had nuclear-localized IRF5 at 3 h poststimulation (Fig. 7B), conﬁrming our previous results with ectopic GFP-tagged IRF5 (12). Using
this 3-h time point as a surrogate indicator of TRAIL-induced IRF5 activation, i.e.,
phosphorylation, that triggers its nuclear accumulation, we next examined IRF5 protein
stability in response to TRAIL after 4 h of treatment with CHX. In the absence of TRAIL,
little change in IRF5 protein levels were observed at 4 h post-CHX treatment (Fig. 4A,
6, and 7C); however, in the presence of TRAIL and CHX, IRF5 degradation was readily
observed, with no change in ␤-actin levels (Fig. 7C). Analysis of the CSN/IRF5 interaction
by immunoprecipitation of THP-1 cells left untreated or treated with TRAIL over a time
course revealed a time-dependent loss of the CSN/IRF5 interaction only in the cells
treated with TRAIL (Fig. 7D). Together, these data support a physiological and funcFebruary 2018 Volume 38 Issue 3 e00493-17
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FIG 7 TRAIL triggers IRF5 nuclear localization and degradation due to loss of the CSN/IRF5 interaction. (A) THP-1 cells were
treated with 25 ng/ml Superkiller TRAIL and intracellularly stained with FITC-conjugated IRF5 (green) and DRAQ5 (red).
Representative single-cell images generated from IDEAS software are shown for each time point. (B) Graphic summary of
endogenous IRF5 nuclear translocation in THP-1 cells after treatment with TRAIL. Data are representative of three independent
experiments. Plotted values are the means ⫾ SD. (C) TRAIL enhances IRF5 degradation. THP-1 cells were cultured under normal
conditions with serum (FBS⫹) or without (serum starved; FBS⫺) and treated with CHX and/or Superkiller TRAIL for 4 h. Cells
were harvested for immunoblot analysis of endogenous IRF5 and ␤-actin. (D) THP-1 cells were left untreated (⫺) or were
treated (⫹) with Superkiller TRAIL over the indicated time course and then harvested for immunoprecipitation with anti-IRF5
antibodies (IP: IRF5) or nonspeciﬁc IgG control antibodies (IP: IgG). The interaction of IRF5 with CSN1 or CSN3 was determined
by immunoblotting. Levels of IRF5 and ␤-actin in whole-cell lysates collected at the 4-h time point for immunoprecipitations
are shown and are representative of what was found at all time points examined.

tional signiﬁcance for the CSN/IRF5 interaction whereby activation/phosphorylation of
IRF5 in response to TRAIL stimulation results in the enhanced degradation of IRF5
proteins due to loss of the CSN/IRF5 interaction.
Loss of the CSN/IRF5 interaction diminishes IRF5 transactivation potential. To
determine whether the interaction of the CSN with IRF5 alters its transactivation
potential, we compared the abilities of full-length and mutant IRF5 to transactivate an
ISRE-containing luciferase reporter. Not surprising, given that the loss of the CSN/IRF5
interaction results in decreased IRF5 protein stability, we found that the Δ455-466
IRF5 mutant had decreased transactivation ability compared to that of full-length IRF5
(Fig. 8A). Since IRF5 is a critical mediator of TLR-induced proinﬂammatory cytokine
expression, we also examined the abilities of full-length and mutant IRF5 to transactivate the TNFA promoter reporter after stimulation of Hek 293/TLR9 cells with CpG
oligodeoxynucleotide (ODN). In agreement with previous reports (22), overexpression
of full-length IRF5 transactivated the TNFA promoter reporter, and this was further
elevated in response to CpG ODN (Fig. 8B). Similar to data from the ISRE reporter, the
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FIG 8 Loss of the CSN/IRF5 interaction diminishes IRF5 transactivation ability. (A) Plasmids encoding Flag-tagged IRF5, the Δ455-466
mutant, and empty vector control (pCMV) were cotransfected with the 5⫻ISRE luciferase promoter reporter, and promoter transactivation was determined by the dual-luciferase assay. Independent experiments were repeated in duplicate wells at least three times;
means ⫾ SD are plotted. (B) Same as that described for panel A except that transactivation of the TNFA promoter reporter was
determined in Hek 293/TLR9 cells left unstimulated (mock) or stimulated with CpG ODN (CpG) or the combination of CpG and MG132.
Three independent experiments were repeated in duplicate; means ⫾ SD are plotted.

Δ455-466 IRF5 mutant was ineffective in its transactivation of the TNFA promoter either
alone or in response to CpG stimulation. To conﬁrm that a loss in IRF5 protein stability
diminishes its transactivation potential, IRF5-transfected and CpG-stimulated cells were
treated with MG132. We found that the transactivation ability of both full-length and
mutant IRF5 was enhanced by the inhibition of proteasome degradation, albeit to
different extents (Fig. 8B). The combined treatment of Δ455-466 IRF5-expressing cells
with CpG and MG132 gave levels of transactivation similar to that of full-length IRF5
stimulated with CpG; the transactivation ability of CpG-induced full-length IRF5 was
greatly enhanced by MG132. Together, these data provide clear evidence that disruption of the CSN/IRF5 interaction decreases IRF5 transactivation ability while inhibition
of IRF5 degradation by the proteasome enhances it.
DISCUSSION
The ability of diverse transcription factors to create multiprotein complexes having
various biological activities is a trademark of eukaryotic gene regulation. Indeed,
protein-protein interactions depict central roles in the activity of IRFs, and diverse
protein complexes have been reported (60–63). In the current study, we identiﬁed the
COP9 signalosome as a new interacting partner of IRF5 that controls its stability
through a mechanism involving the ubiquitin-proteasome pathway. This is a novel
ﬁnding that provides signiﬁcant new insight into an aspect of IRF5 function about
which little is known—the mechanism(s) regulating IRF5 protein stability. Interestingly,
another IRF family member, IRF8 (ICSBP), has been shown to interact directly with CSN2
(64). Although the ﬁndings of Cohen et al. are distinct from ours, these authors reported
that the CSN2/IRF8 interaction resulted in IRF8 phosphorylation that was essential for
interaction with IRF1 and thus downstream regulation of its transcriptional activities
(64). The CSN-associated kinase(s) responsible for IRF8 phosphorylation is not known.
This brings up an interesting possibility for IRF5: can the CSN/IRF5 interaction be used
to identify the critical kinase(s) responsible for IRF5 activation? This is a topic that has
proven elusive to many of us in the ﬁeld of IRF research. Nonetheless, these data
suggest that the CSN complex may have a central role in regulating the stability,
activation, and function of other IRF family members. Indeed, we were able to detect
binding of CSN subunits to endogenous IRF7 as well (J. Korczeniewska and B. J. Barnes,
unpublished data).
When the CSN was ﬁrst puriﬁed from mammalian cells, it copuriﬁed with a Ser/Thr
kinase activity against several important signaling molecules, including IB, p105 (24,
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45), and c-Jun (46). Subsequent studies revealed that p53 (44), NF-B (65, 66), p27kip1
(56), and IRF8 (64) were phosphorylated by CSN-associated kinases. The ﬁrst identiﬁed
CSN-associated kinase was inositol 1,3,4-triphosphate 5/6 kinase (45, 46), and later,
casein kinase 2 (CK2) (42, 44), protein kinase D (PKD) (42), and Akt (50) were identiﬁed.
The CSN-associated protein kinase(s) phosphorylates transcription factors and controls
their stability toward the ubiquitin-proteasome pathway (24, 42, 44, 67). This has been
shown for p53, where CSN-dependent phosphorylation of p53 results in degradation
(44). The CSN complex has been viewed as a scaffold for spatial sequestration of
multiple interacting molecules that exists during the entire protein life cycle and serves
as a pivotal regulatory locus for signal transduction (68, 69).
Throughout the literature, there have been many examples revealing the involvement of the CSN complex in important biological functions, such as cell cycle regulation
(56, 70–73), signal transduction (53, 55, 65, 74), checkpoint control (51, 54, 57, 75–78),
apoptosis (79, 80), and autophagy (81). The CSN is a multifunctional protein complex
involved in these different biological responses through its ability to regulate protein
stability, transcription, protein phosphorylation, and intracellular distribution (68). All of
these functional aspects of the CSN are elements known to be important for IRF5
activation and function. To gain more insight into the functional consequence(s) of the
CSN/IRF5 interaction, we used an endogenous model of TRAIL-induced IRF5 activation.
We found that activation, i.e., phosphorylation (12), of IRF5 in response to TRAIL
treatment resulted in enhanced degradation due to loss of the CSN/IRF5 interaction
(Fig. 7). These data suggest that stimuli inducing IRF5 phosphorylation may trigger its
subsequent degradation; however, previous work in the laboratory has shown that
different stimuli induce different types of IRF5 phosphorylation (13, 19), and therefore some stimuli may work by disrupting the CSN/IRF5 interaction while others
may stabilize it. The physiological signiﬁcance of this interaction was further
explored by examining whether loss of the CSN/IRF5 interaction or inhibition of
IRF5 proteasome degradation by MG132 altered IRF5 transactivation ability. Indeed,
we found that the Δ455-466 mutant was less functional in promoter reporter assays
even after stimulation with the TLR9 ligand CpG. Importantly, stabilization of
full-length and mutant IRF5 proteins by treatment of cells with MG132 further
enhanced IRF5 transactivation potential, supporting the idea that stabilization of
the CSN/IRF5 interaction may enhance IRF5 transactivation ability, as seen in
mock-treated cells (Fig. 8B).
Based on these data, we propose a general model for IRF5 stabilization and
activation (Fig. 9). In unstimulated cells, cytoplasmic IRF5 monomers constitutively
interact with CSN subunits at both the carboxyl- and amino-terminal regions, thus
stabilizing the masking of the DNA binding domain of IRF5 by the AID (Fig. 9A). This,
in turn, leads to effective blocking of IRF5 transcriptional activity and protection from
degradation by the ubiquitin-proteasome pathway. IRF5 is in an inactive yet stable
conformation ready for activation by an extracellular stressor/stimulus (Fig. 9A). Upon
stimulation with TRAIL (or other activation triggers), an as yet to be identiﬁed kinase(s)
uses the CSN complex as a scaffold and phosphorylates IRF5 and/or CSN subunits that
in turn phosphorylate IRF5 (Fig. 9B). The phosphorylation of IRF5 causes a structural
change that leads to dissociation from the CSN complex (Fig. 9C). The loss of the
CSN/IRF5 interaction then results in K48-linked ubiquitination of IRF5 and degradation
by the ubiquitin-proteasome pathway (Fig. 9D), while the remaining “protected” IRF5 is
simultaneously in an active state ready for translocation to the nucleus and transactivation of target genes (Fig. 9E). In this model, a tight control exists between the
activation and degradation of IRF5, which is expected to allow for a very ﬁne-tuned
regulation of IRF5 expression, activation, and target gene expression. This model is
supported by our previous work (19) and more recent ﬁndings from the crystal
structure of IRF5 (48). Together, these data indicate that phosphorylation activates IRF5
by triggering a conformational rearrangement(s) that results in dissociation from the
CSN, release of the C-terminal AID segment from autoinhibitory masking of the DNA
binding domain to a facilitator of dimerization, and cessation of IRF5-mediated signalFebruary 2018 Volume 38 Issue 3 e00493-17
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FIG 9 Model of IRF5 stabilization and activation. (A) In unstimulated cells, cytoplasmic IRF5 monomers constitutively interact with CSN subunits at both the
carboxyl- and amino-terminal regions, thus masking the DNA binding domain of IRF5 by the AID. This leads to the effective blocking of IRF5 transcriptional
activity in unstimulated cells and protects IRF5 from degradation by the ubiquitin-proteasome pathway. (B) Upon stimulation with an activation trigger such
as TRAIL, an as yet to be identiﬁed kinase(s) (kinase x) uses the CSN complex as a scaffold and phosphorylates IRF5 and/or CSN subunits that in turn
phosphorylate IRF5. (C) Phosphorylation of IRF5 results in structural changes that lead to dissociation from the CSN complex. (D) Loss of the CSN/IRF5 interaction
results in K48-linked ubiquitination of IRF5 and degradation by the ubiquitin-proteasome pathway. (E) Some “activated” IRF5 forms homodimers or
heterodimers with other proteins, such as CBP/p300, and translocates to the nucleus, where it binds to promoters of target genes and regulates their
transcription.

ing through its degradation by the ubiquitin-proteasome pathway. Determining the
exact kinetics of IRF5 activation, transcriptional regulation of target genes, and degradation will require further investigation.
Recent support has indicated that IRF5 can be ubiquitinated via K63 linkage in
response to TLR signaling and overexpression of MyD88, TRAF6, or RIP2 (18, 20);
however, current data are controversial with regard to the exact functional consequence of this ubiquitination and whether it alters IRF5 cellular localization and/or
transactivation function. Our data indicate that in the absence of stimulation or
interaction with the CSN complex, IRF5 undergoes K48-linked polyubiquitination that
targets the protein for degradation. It will be important in the near future to further
clarify the types of ubiquitin linkage on IRF5, as well as the kinetics of ubiquitination
and phosphorylation, in order to determine exactly how the CSN contributes to these
two posttranslational events.
Given that IRF5 has been proposed to play a pathogenic role in both SLE and cancer,
it may be relevant to look at alterations in the CSN/IRF5 complex in these two disease
settings, since IRF5 expression is signiﬁcantly upregulated in immune cells of SLE
patients and downregulated in many tumor cell types (2, 5, 10, 14, 15). CSN levels have
indeed been shown to be signiﬁcantly altered in different diseases, and deregulation of
CSN function causes cancer (82, 83). A CSN5-dependent pathway has recently been
identiﬁed that links anti-inﬂammatory and antioxidant gene expression to the TLR
pathway in myeloid cells (84). A clearer understanding of exactly how the CSN complex
regulates IRF5 stability, as well as its involvement in IRF5 activation, may lead to new
avenues for targeting this transcription factor in a disease setting. Data presented
herein support that the CSN binding sites on IRF5 could be used as targets for the
generation of small-molecule inhibitors. Such inhibitors could theoretically attenuate
the levels of IRF5 in a cell and thus may be useful in the treatment of autoimmune
diseases such as SLE, where aberrant IRF5 expression and activation have been detected (5, 59).
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MATERIALS AND METHODS
Expression plasmids. The pCMV-Tag2.IRF5 and pEGFP.IRF5 mammalian expression plasmids were
described previously (2, 19). cDNA of full-length IRF5 variant 4 (residues 1 to 489) was used to create
amino- and carboxyl-terminal deletions, truncated to the amino acids indicated in Fig. 2A. Mutants were
constructed by PCR ampliﬁcation of the full-length IRF5 template with Pfu Turbo DNA polymerase
(Stratagene) and subcloned into EcoRI-SalI sites of plasmid pCMVTag2B (Stratagene) as previously
described (19). Internal deletion mutants at the amino- and carboxyl-terminal ends were generated using
the QuikChange II site-directed mutagenesis kit (Promega). Sequences of the PCR-generated portion of
all constructs were veriﬁed by DNA sequencing and conﬁrmed to express protein by Western blotting
with anti-Flag M2 antibodies (Sigma-Aldrich) or anti-IRF5 antibodies (Cell Signaling). The CSN2 expression
plasmid was a kind gift from B. Z. Levi (Technion, Haifa, Israel), CSN3 was from W. Dubiel (Charite
University, Berlin, Germany), and CSN5 was from M. Neumann (Otto-von-Guericke University, Magdeburg, Germany). The HA-Ub plasmid was a kind gift from I. P. Whitehead (UMDNJ), and the TNFA
promoter reporter was from A. Goldfeld (Harvard Medical School).
Cell culture. Hek 293T cells were a generous gift from I. P. Whitehead (UMDNJ, Newark, NJ) and were
maintained at 37°C (5% CO2) in Dulbecco’s modiﬁed Eagle’s medium (DMEM; high glucose) supplemented with 10% fetal bovine serum (FBS) (Sigma) and 2 mM glutamine without antibiotics. Hek 293
cells stably expressing TLR9 were purchased from InvivoGen and maintained in a similar manner. THP-1
cells were kindly provided by M. B. Mathews (UMDNJ, Newark, NJ) and were grown at 37°C (5% CO2) in
RPMI 1640 supplemented with 10% FBS and 2 mM L-glutamine (Gemini Bio-Products) without antibiotics.
Transient transfections, siRNA knockdown, and cycloheximide chase. Hek 293T cells at 40%
conﬂuence were transfected with IRF5 expression plasmids (2 g/6-well plate, 4 g/60-mm-diameter
plate, 8 g/100-mm-diameter plate) using Lipofectamine 2000 reagent (Invitrogen) in accordance with
the manufacturer’s instructions. The DNA transient transfections were carried out for 32 h unless
otherwise indicated. A modiﬁed protocol from Bi et al. (15) was used to transfect siRNAs into Hek 293T
and THP-1 cells. Hek 293T cells were transiently transfected with 20 pmol of each siRNA, i.e., siGenome
lamin A/C control siRNA (Dharmacon), CSN1 siRNA, or CSN3 siRNA, or were cotransfected simultaneously
with CSN1 and CSN3 siRNAs (Santa Cruz Biotechnology) using Lipofectamine 2000. Twenty-four hours
following transfection, the cells were transfected two more times at the 24-h time points with an
additional 20 pmol of each siRNA. Similarly, 3 ⫻ 106 THP-1 cells were transfected twice (a second time
at the 24-h time point) with 20 pmol of siRNAs using Hypoosmolar electroporation buffer (Eppendorf)
and the Gene Pulser Xcell electroporation system (Bio-Rad). All siRNA transfections were carried out for
72 h, and knockdown efﬁciency was determined by Western blotting. For protein stability assays, Hek
293T cells were fed after transfection with fresh medium and treated with 100 g/ml cycloheximide
(CHX) (Sigma-Aldrich), CHX and 50 M ubiquitin-activating enzyme inhibitor (UBEI-41) (BioGenova), or
CHX and 25 M proteasome inhibitor (MG-132) (EMD Chemicals) for the time periods indicated in Fig.
6A. Similarly, untransfected THP-1 cells were treated with 100 g/ml CHX and/or 25 ng/ml Superkiller
TRAIL (Alexis Biochemicals) for the indicated time periods.
Immunoprecipitation and Western blot analysis. Cells were harvested using lysis buffer (50 mM
Tris-HCl, pH 7.4, 2 mM MgCl2, 100 mM NaCl, 10% glycerol, 1% Nonidet P-40 [Sigma-Aldrich]) supplemented with 0.2 mM protease inhibitor cocktail (Sigma-Aldrich). Protein extracts (300 g) from transfected cells were precipitated with anti-Flag M2 afﬁnity gel antibodies (Sigma-Aldrich) by rotation at 4°C
for 2 h, and immunoprecipitates were washed three times with ice-cold lysis buffer. Proteins were eluted
by boiling the beads for 5 min in 2⫻ SDS loading dye, separated by 10% SDS-PAGE, transferred to a
nitrocellulose membrane, and blocked for 1 h at room temperature with 5% nonfat milk in Tris-buffered
saline–Tween 20 (TBST). Membranes were then incubated with anti-human CSN1 at a 1:3,000 dilution,
CSN2 (1:10,000), CSN4 (1:1,000), CSN5 (1:2,000), CSN6 (1:1,000), CSN7 (1:5,000), and CSN8 (1:5,000) rabbit
polyclonal antibodies (PAb) (Enzo Life Sciences); anti-human CSN3 rabbit monoclonal antibodies (MAb)
(Epitomics) and M2 anti-Flag mouse monoclonal antibodies (Sigma-Aldrich) were used at a 1:10,000
dilution. Anti-human IRF5 rabbit PAb, anti-␤-actin (13E5) rabbit MAb (horseradish peroxidase [HRP]
conjugate), anti-GAPDH (14C10) rabbit MAb (HRP conjugate), anti-K48-linkage-speciﬁc polyubiquitination (D9D5) rabbit MAb, and antiubiquitin (P4D1) mouse MAb (all from Cell Signaling) were used at a
1:1,000 dilution. Secondary HRP-conjugated anti-mouse or anti-rabbit immunoglobulin G antibodies (Cell
Signaling) were used at 1:2,000 dilutions, and proteins were visualized with enhanced chemiluminescence (ECL) detection reagent (GE Healthcare), followed by autoradiography using HyBlot CL ﬁlm
(Denville Scientiﬁc). Immunoprecipitation of endogenous proteins (400 g) was performed in a similar
manner with anti-human IRF5 PAb and normal rabbit IgG antibodies.
Dual-luciferase assay. Hek 293T or Hek 293/TLR9-expressing cells were transiently transfected using
Lipofectamine 2000 (Invitrogen). A 1:1 ratio (2 g each) of luciferase reporter and IRF5 expression
plasmid along with 0.1 g of pRL-CMV as an internal control was used. Cells were left untreated or were
treated with CpG ODN 2216 (Invivogen) and MG132, where indicated, harvested 24 h posttransfection,
and lysed with passive lysis buffer (Promega). Luciferase assays were carried out using the DualLuciferase assay kit according to the manufacturer’s speciﬁcations (Promega). The levels of reporter ﬁreﬂy
luciferase activity were normalized to a constant level of pRL-CMV activity; values were normalized to the
luciferase readings from an empty vector control.
Flow cytometry. Hek 293T cells were transiently transfected with pEGFPC2.IRF5 or pEGFPC2.Δ455466 plasmid as described above. At 48 h posttransfection, cells were collected by trypsinization, washed,
and resuspended in DMEM with 20% FBS. Cells were sorted on a BD FACSAria II SORP into subpopulations expressing low, medium, and high levels of GFP, as described previously (49). Cells expressing
medium levels of GFP-IRF5 were replated and treated with 100 g/ml CHX for 30 to 300 min and then
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collected and ﬁxed in 1% formaldehyde at 4°C. Cells expressing GFP-IRF5 were gated on and IRF5
expression was examined using a FACSCalibur ﬂow cytometer (BD Biosciences). GFP levels were analyzed
using CellQuest software (BD Biosciences). To compare the relative stabilities of full-length IRF5 and the
Δ455-466 mutant, a linear regression analysis of mean ﬂuorescence as a function of time was performed.
A similar analysis was performed independently on transiently transfected cells without sorting ﬁrst for
cells that express medium levels of GFP-IRF5.
Amnis Imagestream. THP-1 cells were treated with 25 ng/ml Superkiller TRAIL (Alexis Biochemicals)
for the indicated time periods. Cells were permeabilized with 0.1% Triton X-100 (Fisher Scientiﬁc) and
intracellularly stained with polyclonal anti-IRF5 antibody (32.5 ng/l; Cell Signaling, Danvers, MA),
followed by FITC-conjugated anti-rabbit secondary antibody (10 ng/l; BD Pharmingen, San Jose, CA);
nuclei were stained with DRAQ5 (10 M) immediately before acquisition. Samples were acquired using
an ImageStream 100 ﬂow cytometer and analyzed with IDEAS software (Amnis Corporation, Seattle, WA)
as recently described (59). In brief, single focused cells were identiﬁed by gating on DRAQ5-positive
events with high DRAQ5 aspect ratios (minor axis divided by major axis, measure of single event) and
high nuclear contrast (measured by the Gradient RMS feature). Nuclear localization of IRF5 was measured
using a morphology mask to determine a similarity score, which quantiﬁes the correlation of pixel values
of the DRAQ5 and IRF5 images on a per-cell basis. A similarity score of ⬎1 was used as a cutoff for
nuclear-localized IRF5; cells in individual bins were visually inspected to conﬁrm subcellular localization
(values of ⬍1 or ⬎1). IDEAS software then generates a composite view of single and merged stains from
all acquired cells.
2-D gel electrophoresis and protein quantiﬁcation. 2-D gel electrophoresis was performed as
previously described (85). Proteins bound to M2 anti-Flag beads were eluted by incubating the beads in
185 l of isoelectric focusing rehydration buffer (7 M urea, 2 M thiourea, 4% CHAPS {3-[(3cholamidopropyl)-dimethylammonio]-1-propanesulfonate}, 100 mM dithiothreitol [DTT], 0.2% biolytes
[pH 5 to 8], 0.01% bromophenol blue, and protease inhibitor). Eluted proteins in a total of 185 l of the
rehydration buffer were applied to 11-cm Bio-Rad ReadyStrip IPG strips (pH 5 to 8) for overnight
rehydration. First-dimension isoelectric focusing was performed on a Bio-Rad (Hercules, CA) Protean
isoelectric focusing system at the University of Medicine and Dentistry of New Jersey Center for
Advanced Proteomics Research (http://njms.rutgers.edu/proweb/), as described by the manufacturer, for
a total focusing time of 75,000 V/h. Strips were equilibrated with equilibration solution I (6 M urea, 0.375
M Tris-HCl, pH 8.8, 2% SDS, 20% glycerol, 2% [wt/vol] DTT) for 15 min and then with equilibration solution
II (6 M urea, 0.375 M Tris-HCl, pH 8.8, 2% SDS, 20% glycerol, 2.5% [wt/vol] iodoacetamide) for 15 min and
directly applied to a 12.5% isocratic SDS-polyacrylamide gel for the second-dimension electrophoresis.
The gel was ﬁxed in a solution consisting of 10% acetic acid and 40% ethanol for 30 min and stained
overnight with SYPRO ruby (Molecular Probes, OR). Gels were destained with a solution containing 10%
methanol and 7.5% acetic acid for 2 h at room temperature and scanned on a Typhoon 9400
variable-mode imager (GE Healthcare, Piscataway, NJ) using a green laser (532 nm) and a 610BP30
emission ﬁlter. Protein quantitation on SYPRO ruby-stained gels was performed by PDQuest 2-D analysis
software (Bio-Rad), and protein spots whose expression levels appreciably changed between the control
and experiment were isolated for mass spectrometric identiﬁcation.
MS and protein identiﬁcation. Protein bands/spots from SYPRO ruby-stained gels were isolated for
protein identiﬁcation. Gel bands were diced into 1-mm3 pieces and washed with 30% acetonitrile (ACN)
in 50 mM ammonium bicarbonate before DTT reduction and iodoacetamide alkylation. Trypsin was used
for digestion at 37°C overnight. The resulting peptides were extracted with 30 l of 1% triﬂuoroacetic
acid, followed by C18 ZipTip desalting. For the mass spectrometry (MS) analysis, peptides were mixed
with 7 mg/ml ␣-cyano-4-hydroxy-cinnamic acid matrix (in 60% ACN) at a 1:1 ratio and spotted onto a
matrix-assisted laser desorption ionization (MALDI) plate; peptides were analyzed on a 4800 MALDI-TOF/
TOF mass analyzer (Applied Biosystems, Framingham, MA). Mass spectra (m/z 880 to 3,200) were
acquired in the positive ion reﬂector mode. The 15 most intense ions were selected for the subsequent
MS-MS sequencing analysis in a 1-kV mode. Protein identiﬁcation was performed by searching the
combined tandem mass spectra against the NCBI (National Center for Biotechnology Information) human
sequence database using a local MASCOT search engine (v.1.9) on a GPS (v.3.5; ABI) server. Proteins
containing at least one peptide with a conﬁdence interval of ⱖ95% were considered to have been
positively identiﬁed.
Preparation of recombinant proteins. Recombinant IRF5, CSN2, CSN3, and CSN5 were generated
by in vitro transcription/translation via the relevant expression plasmids and the TNT coupled
reticulocyte lysate system (Promega) according to the manufacturer’s speciﬁcations. Brieﬂy, by use
of the Transcend nonradioactive translation detection system (Promega), biotinylated lysine residues
were incorporated into nascent IRF5 protein during translation. At the same time, MagneSphere
paramagnetic particles (SA-PMPs) (Promega) were washed three times in 1 ml of PBS, captured using
a magnetic stand, and resuspended in 60 l phosphate-buffered saline (PBS). Biotinylated proteinprotein complexes (50 l) were added to the beads and incubated by rotation at room temperature
for 30 min. Following the binding reaction, bead-protein complexes were washed three times with
1 ml of PBS and captured with the magnetic stand; bound proteins were eluted by boiling in 2⫻ SDS
loading dye and resolving on a 10% SDS-PAGE gel. Membranes were immunoblotted with the
indicated antibodies.
Statistical analysis. Statistical analysis was done with the two-tailed Student t test or Mann-Whitney
U test when variables were not normally distributed. Data are presented as the mean ⫾ standard
deviation (SD) (normal distribution) or the mean ⫾ standard error of the mean (SEM) (nonnormal
February 2018 Volume 38 Issue 3 e00493-17
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distribution). A P value of ⬍0.05 was considered signiﬁcant. Statistical analyses were performed using
Prism 4.0 (GraphPad Software, San Diego, CA).
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